Leadership team

Combining expertise across science, medicine and investing.

Pablo Legorreta

Founder & Chief Executive Officer

Pablo is the founder, CEO and Chairman of Royalty Pharma plc. Since its founding in 1996, Royalty Pharma has been the pioneer and market leader in royalty funding of life science innovation. The company’s collaborations span the entire research and development ecosystem, from academic institutions, research hospitals and not-for-profits to small- and mid-cap biotechnology companies and global pharmaceutical companies. To date, Royalty Pharma has deployed more than $20 billion of capital to advance innovation in the biopharmaceutical industry.

Pablo is a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. He is also a co-founder of ProKidney, LLC, a biotech company developing pioneering therapies that have the potential to change the lives of people with chronic kidney disease.

Pablo is also the founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities.

Pablo serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, the Hospital for Special Surgery, Pasteur Foundation (US), Open Medical Institute and Park Avenue Armory.

Prior to founding Royalty Pharma, Pablo was an investment banker at Lazard Frères in Paris and New York.

Terrance Coyne

Chief Financial Officer

Terry joined Royalty Pharma in 2010. Previously, Terry was a biotechnology analyst at JP Morgan and Rodman & Renshaw, and began his career at Wyeth Pharmaceuticals. Terry has a BS in business administration from La Salle University and an MBA from La Salle University.

Christopher Hite

Vice Chairman

Chris has over 25 years of experience advising biopharmaceutical companies on mergers and acquisitions and capital formation. Prior to joining Royalty Pharma in 2020, Chris was an investment banker at Citi where he was the Global Head of Healthcare for nearly 12 years and most recently a vice chairman of Banking, Capital Markets and Advisory (“BCMA”) and also sat on the Executive Committee of BCMA. Prior to joining Citi, Chris was the Global Head of Healthcare Investment Banking at Lehman Brothers.  Chris serves on the Board of Trustees at Lehigh University, the Board of Advisors of Faster Cures, a center of the Milken Institute, and served on the Board of Directors of Acceleron Pharma Inc. (Nasdaq: XLRN) until its acquisition by Merck in November 2021 for $11.5 billion. Chris has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.

George Lloyd

Chief Legal Officer & Investments

George focuses on transaction structuring and execution and also leads the legal and compliance function at Royalty Pharma. George joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. George was previously a partner in Goodwin Procter’s Private Equity group and an associate in Davis, Polk & Wardwell’s New York and Paris offices. George has an AB from Princeton University and a JD from New York University Law School.

Arthur McGivern

General Counsel & Investments

Art joined Royalty Pharma in 2022. Previously, Art was a partner in Goodwin Procter’s Life Sciences practice. Art holds a BS in civil engineering from Tufts University and a JD from Boston University.

Ashwin Pai, MD


Ashwin joined Royalty Pharma in 2023. Ashwin has nearly two decades of experience advising biopharmaceutical companies on mergers and acquisitions as well as capital formation. Prior to joining Royalty Pharma, Ashwin was a managing director of Morgan Stanley and led the firm’s West Coast Biotechnology Investment Banking practice. Ashwin received both his MD in the accelerated Honors Program in Medical Education and his BA in economics with highest distinction from Northwestern University.

Jim Reddoch, PhD

Chief Scientific Officer & Investments

Jim has more than 25 years of experience in biopharma investing. He leverages our science expertise to identify trends and find new investment opportunities. He led the Research and Investments team from 2008 to 2020. Prior to joining Royalty Pharma in 2008, Jim led healthcare research at FBR Capital Markets. Previously, Jim was a biotechnology analyst at Bank of America and CIBC World Markets. Jim serves on the Board of the Leukemia and Lymphoma Society (LLS), the Board of Avillion, a London-based drug development company and on Memorial Sloan Kettering Cancer Center’s External Review Board for its Technology Development Fund. Jim has a BA from Furman University, a PhD in biochemistry and molecular genetics from the UAB and was a postdoctoral fellow at Yale University.

Marshall Urist, MD, PhD

Head of Research & Investments

Marshall joined Royalty Pharma in 2013. Previously, Marshall was an executive director and the senior biotechnology analyst at Morgan Stanley. Marshall has a BA, Phi Beta Kappa, from Johns Hopkins University, a PhD from Columbia University and an MD from Columbia University.

Working at Royalty Pharma

A truly team-oriented environment
Our culture makes it easy to retain talent, resulting in long-tenured teams with low staff turnover.

Diverse skills and backgrounds
Our colleagues come from 16 nations and bring deep expertise in the fields of science, medicine and investing.

Owner-operator mindset
Our team and our shareholders are aligned, with one third of shares owned by employees and the board.

Learn more about our firm

We cultivate an environment that fosters collaboration and provides opportunities to learn and grow.

Alessandra Sassun,
Head of Human Capital

Stay up to date

Subscribe to Royalty Pharma news and alerts